IOVA7.76+0.13 (+1.70%) session● PRIOR SESSION CLOSE

IOVAcited research thesis

IOVA — what changed and why it matters

House verdict · IOVA · multi-desk debate + self-falsification

No sealed verdict on IOVA yet

No debate has been run on IOVA; debates rotate through a watchlist. The conviction call below is the signal engine’s output — one input to a debate, not a multi-desk verdict. Sealed debates on other names, each with its falsification check, are available.

Open the Glass Box →

Individual · $49 a monthThe conviction call on IOVA — outside the public coverage list

Covered names include the conviction call in the sealed record at no charge. IOVA is outside public coverage; running the signal engine on it requires a seat. The panels above do not depend on it.

Start checkout →

PRE-EARNINGS THESIS — written 2026-08-25, before the 2026-11-05 earnings report; nothing below reflects that report. A refresh is queued for the session a covered name reports or moves sharply. A same-session re-derive is queued when a covered name prints or moves sharply; until the refreshed read lands, nothing below reflects that report.

0 of 9 figures below re-derived from a sourcewritten 2026-08-25

This thesis is 82 days old. Statements below are as of 2026-08-25.

IOVA — what moved and why today

Context (knowledge graph)

AtlasVector tracks 10 related entities for IOVA in its knowledge graph. ^[c1]

What changed

Iovance Biotherapeutics Stock Is Trending Friday: What's Going On?
Why Iovance Biotherapeutics Stock Hit 52-Week High
sell-side note Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $7

Key takeaways

Iovance Biotherapeutics Stock Is Trending Friday: What's Going On?
Why Iovance Biotherapeutics Stock Hit 52-Week High
sell-side note Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $7

Headlines · IOVA AS OF 2026-11-15 07:08Z

11-06 10:23ZIOVA Q3 Earnings Call Highlights Amtagvi Growth and Pipeline ProgressZacks Investment Research
11-04 14:02ZAMRX Q3 Earnings & Sales Beat Estimates, FY'26 Guidance RaisedZacks Investment Research
11-03 13:51ZViatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?Zacks Investment Research
11-02 16:19ZIovance Gears Up to Report Q3 Earnings: Here's What to ExpectZacks Investment Research

Provenance

verdicts, debates and hash-chained audit seals recorded against IOVA

Instruments 1

IOVA2026-11-13

Session bars 5

IOVA · Fri Nov 13 session barIOVA2026-11-13
IOVA · Thu Nov 12 session barIOVA2026-11-12
IOVA · Wed Nov 11 session barIOVA2026-11-11
IOVA · Tue Nov 10 session barIOVA2026-11-10
IOVA · Mon Nov 09 session barIOVA2026-11-09

Screen metrics 1

IOVA · screen metrics · Fri Nov 13IOVA2026-11-13

7 recorded entities · 6 links. synthetic = the row is flagged as built on synthetic inputs; no provenance = the store holds no synthetic flag for the row. Unmarked rows are flagged non-synthetic. Chain seals list sequence number, event key and SHA-256 chain hash. Verify seal opens the verdict's proof panel, where the sealed record is re-hashed in the browser and compared against the seal.

Cited sources · 5

[c1]AtlasVector knowledge graphgraph context for IOVA

[c2]NewswireIovance Biotherapeutics Stock Is Trending Friday: What's Going On?

[c3]NewswireWhy Iovance Biotherapeutics Stock Hit 52-Week High

[c4]Newswiresell-side note Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $7

[c5]AtlasVector valuation spineconsensus valuation

The full record is in AtlasVector.

Standing monitors, multi-desk debate, audited paper trading and a persistent research record.

Open AtlasVector →